SOTIO is conducting a Phase 2 (NCT05619172) AURELIO-05 trial studying nanrilkefusp alfa (formerly SOT101) in combination with cetuximab. The trial is an open-label, single-arm, multicenter study that is evaluating the efficacy and safety of nanrilkefusp alfa in combination with cetuximab in patients with RAS wild-type colorectal cancer. The Phase 2 trial will enroll up to 52 patients across the trial sites in Belgium, Spain, Czech Republic, Italy and France. The first patient was dosed at the University of Ziekenhuis Hostpial in Gent, Belgium, under the supervision of Eric Van Cutsem, M.D., Ph.D., principal investigator.